Research programme: ubiquitin specific protease inhibitors - Hybrigenics

Drug Profile

Research programme: ubiquitin specific protease inhibitors - Hybrigenics

Alternative Names: HBX 19,818; HBX 41,108; HBX 96,819; USP inhibitors - Hybrigenics; USP8 inhibitors - Hybrigenics

Latest Information Update: 12 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hybrigenics
  • Class Small molecules
  • Mechanism of Action Ubiquitin protein ligase complex inhibitors; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Pituitary ACTH hypersecretion

Most Recent Events

  • 06 Jun 2017 Hybrigenics has patnet protection for USP8 inhibitors in Europe
  • 06 Jun 2017 Early research in Pituitary ACTH hypersecretion in France (unspecified route)
  • 24 Apr 2012 Preclinical pharmacodynamics data in Cancer released by Hybrigenics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top